Preclinical molecules

Explore our library of optimised molecules for use in preclinical models

Configure Image Component

Submit a proposal and help drive innovative science

Join forces to transform drug discovery

Identifying disease targets for active molecules is integral to modern drug discovery. Our aim is to make high-quality life science research tools available to the external research community to accelerate innovative scientific research. These include antibodies, PROTAC molecules and oligonucleotides that have been developed as part of our drug discovery programmes. By combining our resources with your insights, we can generate high-quality preclinical data that enhances the understanding of disease pathways and supports the future generation of life-changing medicines.

For a description of the types of molecules available, please see here.

Programme details

Submission status: Active

No submission deadline, please apply any time.

Collapse all
Expand all

Configure Accordion Item: - What are we looking for?

accordionUniqueIDDescription - acc-head1

What are we looking for?

Configure Accordion Item: - What are we looking for?

We are looking for collaborators to partner with us, with each other, and with public or private funding bodies to brainstorm, design, and execute preclinical translational research.

Configure Accordion Item: - Benefits

accordionUniqueIDDescription - acc-head2

Benefits

Configure Accordion Item: - Benefits

By working with us, you gain access to highly optimised tool molecules for use in your research models. In addition, we can provide you with the data and expertise to support your experimental design and interpretation of results. We encourage publication of the data and insights generated from the collaboration. We do not provide funding to support this work, but we will provide a letter of support for you to include in your grant funding application.

Configure Accordion Item: - Who is this for?

accordionUniqueIDDescription - acc-head3

Who is this for?

Configure Accordion Item: - Who is this for?

This programme is open to basic and applied researchers working in academic settings across all geographies.

Configure Accordion Item: - How to apply

accordionUniqueIDDescription - acc-head4

How to apply

Configure Accordion Item: - How to apply

Our diverse sets of preclinical molecules

We share highly optimised tool molecules to further explore the biology underlying disease mechanisms. These tools have optimised physical and chemical properties making them suitable for advanced research in translational or animal models. These molecules are available for hypothesis-based research proposals in quantities justified by the research plans. In many cases, additional molecules targeting the same mechanism can be made available to best suit the needs of your research.

The generation and characterisation of high-quality, biological agents are fundamental tools for preclinical researchers in the life sciences. We have developed the skills and expertise to generate highly specific antibodies and recombinant proteins for use in our portfolio projects, many of which are not available commercially. The goal of sharing these tools is to offer researchers a unique set of reagents that can be used to generate deeper insight into the molecular pathways that regulate cellular processes.

These agents modulate gene expression primarily by gene silencing or RNA interference. As part of our commitment to sharing research tools for the advancement of science, we are offering access to a small selection of ASO and siRNA tools. Through collaboration with external scientists, our is goal is to generate greater insight into these potential new drug modalities and/or the mechanism of action for their biological target.

This offering includes:

Clinically validated design and chemistries with high potency, safety and stability
Both target and control tools
”Naked” and conjugatable versions of the tools

These tools are provided at >85% purity (by HPLC).

PROteolysis Targeting Chimeras (PROTACs) is a new small molecule drug modality capable of degrading unwanted or harmful proteins in cells with high specificity. PROTACs have the potential to target previously ‘undruggable’ proteins as, unlike inhibitors, they can remove all protein functions (enzymatic, scaffolding, regulatory). PROTAC molecules consist of a protein of interest (POI) ligand and an E3 ubiquitin ligase (E3) recruiting ligand connected by an optimal linker. Upon ligand binding, the POI and E3 ligase form a ternary complex that initiates degradation of the target protein.

We are focussed on advancing a PROTAC portfolio across our therapeutic areas and on achieving a deeper understanding of PROTAC efficacy, PK-PD relationship and safety.

The goal of offering these PROTAC molecules through Open Innovation is to enable external scientists access to tool compounds to use in their research to generate data that could provide deeper insight into biology through unlocking the potential of this modality as a next-generation therapeutic.